Metropolitan Life Insurance Company (MetLife)’s Fulgent Genetics FLGT Stock Holding History

Metropolitan Life Insurance Company (MetLife)’s Portfolio FLGT Stock Details FLGT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-1,099	Closed	-$23.8K	–	778
2024 Q1	$23.8K	Sell	1,099 -245	-18%	-$6.08K	﹤0.01%	1772
2023 Q4	$38.9K	Hold	1,344	–	–	﹤0.01%	1580
2023 Q3	$35.9K	Buy	1,344 +212	+19%	+$7.24K	﹤0.01%	1579
2023 Q2	$41.9K	Hold	1,132	–	–	﹤0.01%	1525
2023 Q1	$35.3K	Sell	1,132 -208	-16%	-$6.69K	﹤0.01%	1581
2022 Q4	$39.9K	Hold	1,340	–	–	﹤0.01%	1607
2022 Q3	$51.1K	Hold	1,340	–	–	﹤0.01%	1449
2022 Q2	$73.1K	Hold	1,340	–	–	﹤0.01%	1258
2022 Q1	$83.6K	Sell	1,340 -4,339	-76%	-$286K	﹤0.01%	1316
2021 Q4	$571K	Hold	5,679	–	–	0.01%	1333
2021 Q3	$511K	Hold	5,679	–	–	0.01%	1450
2021 Q2	$524K	Buy	5,679 +1,662	+41%	+$133K	0.01%	1493
2021 Q1	$388K	Hold	4,017	–	–	0.01%	1575
2020 Q4	$209K	Buy	4,017 +752	+23%	+$31.4K	﹤0.01%	1909
2020 Q3	$131K	Buy	+3,265	New	+$102K	﹤0.01%	2059

Other funds holding FLGT

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

PWAM

Park West Asset Management San Francisco, California $1.18B AUM 47.25% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

DSCM

Divisadero Street Capital Management Miami, Florida $2.39B AUM 134.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Metropolitan Life Insurance Company (MetLife)'s FLGT Position: Q2 2024 in Review

Metropolitan Life Insurance Company (MetLife) sold out of Fulgent Genetics (FLGT) in Q2 2024, closing a stake of 1,099 shares — an estimated $23.8K sold.

Metropolitan Life Insurance Company (MetLife) first reported a position in FLGT in Q3 2020 and held it in 15 quarters. The position peaked at $571K in Q4 2021. 173 funds tracked by Wall St. Rank hold FLGT as of Q2 2024.

Metropolitan Life Insurance Company (MetLife) reported no remaining Fulgent Genetics position as of Q2 2024 after selling out during the quarter.
Metropolitan Life Insurance Company (MetLife) sold 1,099 Fulgent Genetics shares in Q2 2024, an estimated $23.8K.
Metropolitan Life Insurance Company (MetLife) first reported a position in Fulgent Genetics in Q3 2020 and held it in 15 quarters.
Metropolitan Life Insurance Company (MetLife)'s Fulgent Genetics position peaked at $571K in Q4 2021.
173 funds tracked by Wall St. Rank held Fulgent Genetics as of Q2 2024.

Based on Metropolitan Life Insurance Company (MetLife)'s 13F filing for Q2 2024, filed 13 Aug 2024.